United Therapeutics Co. (NASDAQ:UTHR) Holdings Raised by Gotham Asset Management LLC

Gotham Asset Management LLC increased its stake in United Therapeutics Co. (NASDAQ:UTHR) by 17.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,179 shares of the biotechnology company’s stock after purchasing an additional 9,121 shares during the quarter. Gotham Asset Management LLC owned approximately 0.14% of United Therapeutics worth $21,586,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of UTHR. Wealthfront Advisers LLC grew its position in United Therapeutics by 2,090,573.5% during the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock worth $6,462,018,000 after purchasing an additional 18,313,424 shares in the last quarter. Norges Bank acquired a new stake in shares of United Therapeutics in the fourth quarter worth $151,764,000. FMR LLC grew its holdings in shares of United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock valued at $519,170,000 after buying an additional 393,777 shares in the last quarter. Thrivent Financial for Lutherans raised its position in United Therapeutics by 1,325.5% during the fourth quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company’s stock valued at $72,085,000 after buying an additional 189,967 shares during the period. Finally, AustralianSuper Pty Ltd lifted its stake in United Therapeutics by 577.1% in the 4th quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company’s stock worth $66,962,000 after acquiring an additional 161,751 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, May 2nd. Wells Fargo & Company reiterated an “equal weight” rating and issued a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. JPMorgan Chase & Co. decreased their target price on shares of United Therapeutics from $355.00 to $350.00 and set an “overweight” rating for the company in a research note on Thursday, May 1st. Bank of America raised shares of United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 price target on the stock in a research note on Monday, April 21st. Finally, HC Wainwright reissued a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $392.00.

United Therapeutics Price Performance

UTHR opened at $301.42 on Friday. United Therapeutics Co. has a fifty-two week low of $263.56 and a fifty-two week high of $417.82. The company has a market capitalization of $13.60 billion, a P/E ratio of 13.24, a P/E/G ratio of 0.97 and a beta of 0.58. The firm’s fifty day moving average price is $300.53 and its two-hundred day moving average price is $342.14.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts’ consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million for the quarter, compared to analysts’ expectations of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.17 earnings per share. On average, equities research analysts expect that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the company’s stock in a transaction on Thursday, April 17th. The stock was sold at an average price of $283.78, for a total value of $3,121,580.00. Following the sale, the executive vice president now directly owns 36,781 shares in the company, valued at $10,437,712.18. This represents a 23.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the transaction, the director now directly owns 8,480 shares of the company’s stock, valued at approximately $2,703,424. The trade was a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 75,500 shares of company stock valued at $24,245,880. Corporate insiders own 11.90% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.